nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—BMX—skin of body—penile cancer	0.0131	0.0145	CbGeAlD
Bosutinib—BMX—urethra—penile cancer	0.0126	0.0139	CbGeAlD
Bosutinib—DSTYK—urethra—penile cancer	0.0126	0.0139	CbGeAlD
Bosutinib—EIF2AK1—urethra—penile cancer	0.0121	0.0134	CbGeAlD
Bosutinib—CDK2—skin of body—penile cancer	0.0119	0.0132	CbGeAlD
Bosutinib—VRK2—urethra—penile cancer	0.0118	0.013	CbGeAlD
Bosutinib—SYK—urethra—penile cancer	0.0115	0.0128	CbGeAlD
Bosutinib—STK26—urethra—penile cancer	0.0113	0.0125	CbGeAlD
Bosutinib—WEE1—urethra—penile cancer	0.0109	0.012	CbGeAlD
Bosutinib—DMPK—urethra—penile cancer	0.0109	0.012	CbGeAlD
Bosutinib—PLK2—skin of body—penile cancer	0.0105	0.0116	CbGeAlD
Bosutinib—STK25—urethra—penile cancer	0.0104	0.0115	CbGeAlD
Bosutinib—PLK2—urethra—penile cancer	0.0101	0.0112	CbGeAlD
Bosutinib—STK24—skin of body—penile cancer	0.00982	0.0109	CbGeAlD
Bosutinib—IKBKE—lymph node—penile cancer	0.00977	0.0108	CbGeAlD
Bosutinib—CAMK1D—urethra—penile cancer	0.00952	0.0105	CbGeAlD
Bosutinib—TYRO3—skin of body—penile cancer	0.0095	0.0105	CbGeAlD
Bosutinib—STK24—urethra—penile cancer	0.00941	0.0104	CbGeAlD
Bosutinib—FER—urethra—penile cancer	0.0091	0.0101	CbGeAlD
Bosutinib—MAP4K2—urethra—penile cancer	0.00862	0.00955	CbGeAlD
Bosutinib—BMPR2—skin of body—penile cancer	0.00851	0.00942	CbGeAlD
Bosutinib—BMPR2—urethra—penile cancer	0.00816	0.00903	CbGeAlD
Bosutinib—STK36—urethra—penile cancer	0.00809	0.00896	CbGeAlD
Bosutinib—EPHB3—urethra—penile cancer	0.00809	0.00896	CbGeAlD
Bosutinib—MERTK—urethra—penile cancer	0.008	0.00885	CbGeAlD
Bosutinib—MAP2K1—skin of body—penile cancer	0.00792	0.00876	CbGeAlD
Bosutinib—STK35—skin of body—penile cancer	0.00792	0.00876	CbGeAlD
Bosutinib—CSK—skin of body—penile cancer	0.00786	0.0087	CbGeAlD
Bosutinib—MAP4K4—urethra—penile cancer	0.00785	0.00869	CbGeAlD
Bosutinib—CSNK1A1—skin of body—penile cancer	0.00781	0.00865	CbGeAlD
Bosutinib—BCR—urethra—penile cancer	0.0078	0.00863	CbGeAlD
Bosutinib—MAP3K12—urethra—penile cancer	0.00774	0.00857	CbGeAlD
Bosutinib—EPHB2—L1CAM interactions—SCN10A—penile cancer	0.00769	0.0797	CbGpPWpGaD
Bosutinib—CSK—urethra—penile cancer	0.00753	0.00834	CbGeAlD
Bosutinib—CSNK1A1—urethra—penile cancer	0.00748	0.00828	CbGeAlD
Bosutinib—CLK1—urethra—penile cancer	0.00744	0.00823	CbGeAlD
Bosutinib—HCK—urethra—penile cancer	0.00744	0.00823	CbGeAlD
Bosutinib—CAMK2G—urethra—penile cancer	0.0073	0.00808	CbGeAlD
Bosutinib—CSNK1E—skin of body—penile cancer	0.00724	0.00801	CbGeAlD
Bosutinib—LRRK2—urethra—penile cancer	0.00723	0.00801	CbGeAlD
Bosutinib—SIK1—skin of body—penile cancer	0.00713	0.00789	CbGeAlD
Bosutinib—ERBB3—skin of body—penile cancer	0.00699	0.00773	CbGeAlD
Bosutinib—MAP2K2—skin of body—penile cancer	0.00697	0.00771	CbGeAlD
Bosutinib—CSNK1E—urethra—penile cancer	0.00694	0.00768	CbGeAlD
Bosutinib—SIK1—urethra—penile cancer	0.00683	0.00756	CbGeAlD
Bosutinib—IRAK4—urethra—penile cancer	0.00683	0.00756	CbGeAlD
Bosutinib—PTK2—skin of body—penile cancer	0.00678	0.0075	CbGeAlD
Bosutinib—EPHA4—urethra—penile cancer	0.00676	0.00748	CbGeAlD
Bosutinib—MAP2K2—urethra—penile cancer	0.00668	0.00739	CbGeAlD
Bosutinib—ULK3—urethra—penile cancer	0.00668	0.00739	CbGeAlD
Bosutinib—MAP3K7—urethra—penile cancer	0.00657	0.00727	CbGeAlD
Bosutinib—PTK2—urethra—penile cancer	0.00649	0.00719	CbGeAlD
Bosutinib—TBK1—urethra—penile cancer	0.00649	0.00719	CbGeAlD
Bosutinib—TLK1—lymph node—penile cancer	0.00647	0.00716	CbGeAlD
Bosutinib—AXL—skin of body—penile cancer	0.00645	0.00714	CbGeAlD
Bosutinib—PRKCQ—lymph node—penile cancer	0.00638	0.00707	CbGeAlD
Bosutinib—RPS6KB1—urethra—penile cancer	0.00624	0.00691	CbGeAlD
Bosutinib—LCK—urethra—penile cancer	0.00621	0.00687	CbGeAlD
Bosutinib—FGR—urethra—penile cancer	0.00621	0.00687	CbGeAlD
Bosutinib—AXL—urethra—penile cancer	0.00618	0.00684	CbGeAlD
Bosutinib—FYN—skin of body—penile cancer	0.00604	0.00669	CbGeAlD
Bosutinib—CLK3—lymph node—penile cancer	0.00599	0.00663	CbGeAlD
Bosutinib—DSTYK—lymph node—penile cancer	0.00599	0.00663	CbGeAlD
Bosutinib—BMX—lymph node—penile cancer	0.00599	0.00663	CbGeAlD
Bosutinib—SLK—urethra—penile cancer	0.00595	0.00659	CbGeAlD
Bosutinib—BLK—lymph node—penile cancer	0.00592	0.00655	CbGeAlD
Bosutinib—EPHB4—urethra—penile cancer	0.00591	0.00654	CbGeAlD
Bosutinib—MAP3K3—skin of body—penile cancer	0.0059	0.00653	CbGeAlD
Bosutinib—CASK—lymph node—penile cancer	0.00585	0.00648	CbGeAlD
Bosutinib—PHKG1—lymph node—penile cancer	0.00585	0.00648	CbGeAlD
Bosutinib—EPHA2—urethra—penile cancer	0.0058	0.00641	CbGeAlD
Bosutinib—EIF2AK1—lymph node—penile cancer	0.00579	0.00641	CbGeAlD
Bosutinib—FYN—urethra—penile cancer	0.00579	0.0064	CbGeAlD
Bosutinib—TXK—lymph node—penile cancer	0.00567	0.00628	CbGeAlD
Bosutinib—MAP4K5—urethra—penile cancer	0.00565	0.00626	CbGeAlD
Bosutinib—MAP3K3—urethra—penile cancer	0.00565	0.00626	CbGeAlD
Bosutinib—FES—lymph node—penile cancer	0.00561	0.00621	CbGeAlD
Bosutinib—VRK2—lymph node—penile cancer	0.00561	0.00621	CbGeAlD
Bosutinib—TNIK—lymph node—penile cancer	0.0055	0.00609	CbGeAlD
Bosutinib—SYK—lymph node—penile cancer	0.0055	0.00609	CbGeAlD
Bosutinib—CDK2—lymph node—penile cancer	0.00545	0.00604	CbGeAlD
Bosutinib—STK26—lymph node—penile cancer	0.0054	0.00598	CbGeAlD
Bosutinib—SRC—skin of body—penile cancer	0.00524	0.0058	CbGeAlD
Bosutinib—YES1—urethra—penile cancer	0.00522	0.00578	CbGeAlD
Bosutinib—CHEK2—lymph node—penile cancer	0.00522	0.00578	CbGeAlD
Bosutinib—WEE1—lymph node—penile cancer	0.00517	0.00573	CbGeAlD
Bosutinib—DMPK—lymph node—penile cancer	0.00517	0.00573	CbGeAlD
Bosutinib—TAOK3—urethra—penile cancer	0.00515	0.00571	CbGeAlD
Bosutinib—STK25—lymph node—penile cancer	0.00494	0.00547	CbGeAlD
Bosutinib—EPHA3—lymph node—penile cancer	0.00491	0.00543	CbGeAlD
Bosutinib—PLK2—lymph node—penile cancer	0.0048	0.00532	CbGeAlD
Bosutinib—SIK3—lymph node—penile cancer	0.00477	0.00528	CbGeAlD
Bosutinib—CSF1R—skin of body—penile cancer	0.00471	0.00521	CbGeAlD
Bosutinib—MAP2K5—urethra—penile cancer	0.00462	0.00511	CbGeAlD
Bosutinib—STK4—lymph node—penile cancer	0.00459	0.00508	CbGeAlD
Bosutinib—CAMK1D—lymph node—penile cancer	0.00454	0.00502	CbGeAlD
Bosutinib—CSF1R—urethra—penile cancer	0.00451	0.00499	CbGeAlD
Bosutinib—STK24—lymph node—penile cancer	0.00449	0.00497	CbGeAlD
Bosutinib—FER—lymph node—penile cancer	0.00434	0.00481	CbGeAlD
Bosutinib—ALK—lymph node—penile cancer	0.00434	0.00481	CbGeAlD
Bosutinib—MAP4K1—lymph node—penile cancer	0.00425	0.00471	CbGeAlD
Bosutinib—BTK—lymph node—penile cancer	0.00423	0.00468	CbGeAlD
Bosutinib—PDGFRB—skin of body—penile cancer	0.00418	0.00462	CbGeAlD
Bosutinib—TNK2—lymph node—penile cancer	0.00417	0.00462	CbGeAlD
Bosutinib—MAP4K2—lymph node—penile cancer	0.00411	0.00455	CbGeAlD
Bosutinib—STK3—lymph node—penile cancer	0.00406	0.00449	CbGeAlD
Bosutinib—PDGFRB—urethra—penile cancer	0.004	0.00443	CbGeAlD
Bosutinib—BMPR2—lymph node—penile cancer	0.00389	0.00431	CbGeAlD
Bosutinib—EPHB3—lymph node—penile cancer	0.00386	0.00427	CbGeAlD
Bosutinib—STK36—lymph node—penile cancer	0.00386	0.00427	CbGeAlD
Bosutinib—MERTK—lymph node—penile cancer	0.00382	0.00422	CbGeAlD
Bosutinib—MAP4K4—lymph node—penile cancer	0.00374	0.00414	CbGeAlD
Bosutinib—ABL1—skin of body—penile cancer	0.00372	0.00412	CbGeAlD
Bosutinib—BCR—lymph node—penile cancer	0.00372	0.00412	CbGeAlD
Bosutinib—NUAK2—lymph node—penile cancer	0.00372	0.00412	CbGeAlD
Bosutinib—MAP3K12—lymph node—penile cancer	0.00369	0.00409	CbGeAlD
Bosutinib—STK35—lymph node—penile cancer	0.00362	0.004	CbGeAlD
Bosutinib—MAP2K1—lymph node—penile cancer	0.00362	0.004	CbGeAlD
Bosutinib—CSK—lymph node—penile cancer	0.00359	0.00398	CbGeAlD
Bosutinib—CSNK1A1—lymph node—penile cancer	0.00357	0.00395	CbGeAlD
Bosutinib—ABL1—urethra—penile cancer	0.00356	0.00395	CbGeAlD
Bosutinib—HCK—lymph node—penile cancer	0.00355	0.00393	CbGeAlD
Bosutinib—CLK1—lymph node—penile cancer	0.00355	0.00393	CbGeAlD
Bosutinib—EPHB3—Axon guidance—SCN10A—penile cancer	0.00353	0.0366	CbGpPWpGaD
Bosutinib—ABL2—lymph node—penile cancer	0.00352	0.0039	CbGeAlD
Bosutinib—BMP2K—lymph node—penile cancer	0.00348	0.00385	CbGeAlD
Bosutinib—CAMK2G—lymph node—penile cancer	0.00348	0.00385	CbGeAlD
Bosutinib—LRRK2—lymph node—penile cancer	0.00345	0.00382	CbGeAlD
Bosutinib—EGFR—lymph node—penile cancer	0.00344	0.00381	CbGeAlD
Bosutinib—PTK2B—lymph node—penile cancer	0.00336	0.00372	CbGeAlD
Bosutinib—FES—Axon guidance—SCN10A—penile cancer	0.00332	0.0344	CbGpPWpGaD
Bosutinib—CSNK1E—lymph node—penile cancer	0.00331	0.00366	CbGeAlD
Bosutinib—SIK1—lymph node—penile cancer	0.00326	0.0036	CbGeAlD
Bosutinib—IRAK4—lymph node—penile cancer	0.00326	0.0036	CbGeAlD
Bosutinib—EPHA4—lymph node—penile cancer	0.00322	0.00357	CbGeAlD
Bosutinib—ERBB3—lymph node—penile cancer	0.00319	0.00353	CbGeAlD
Bosutinib—MAP2K2—lymph node—penile cancer	0.00318	0.00352	CbGeAlD
Bosutinib—ULK3—lymph node—penile cancer	0.00318	0.00352	CbGeAlD
Bosutinib—MAP3K2—lymph node—penile cancer	0.00316	0.0035	CbGeAlD
Bosutinib—EPHA5—Axon guidance—SCN10A—penile cancer	0.00315	0.0326	CbGpPWpGaD
Bosutinib—ABL2—Axon guidance—SCN10A—penile cancer	0.00315	0.0326	CbGpPWpGaD
Bosutinib—EPHA3—Axon guidance—SCN10A—penile cancer	0.00315	0.0326	CbGpPWpGaD
Bosutinib—MAP3K7—lymph node—penile cancer	0.00313	0.00347	CbGeAlD
Bosutinib—PTK2—lymph node—penile cancer	0.0031	0.00343	CbGeAlD
Bosutinib—TBK1—lymph node—penile cancer	0.0031	0.00343	CbGeAlD
Bosutinib—MAP2K2—L1CAM interactions—SCN10A—penile cancer	0.00309	0.032	CbGpPWpGaD
Bosutinib—EPHA8—Axon guidance—SCN10A—penile cancer	0.00304	0.0314	CbGpPWpGaD
Bosutinib—IRAK1—lymph node—penile cancer	0.00304	0.00336	CbGeAlD
Bosutinib—EPHB4—Axon guidance—SCN10A—penile cancer	0.003	0.0311	CbGpPWpGaD
Bosutinib—EPHA4—Axon guidance—SCN10A—penile cancer	0.003	0.0311	CbGpPWpGaD
Bosutinib—RPS6KB1—lymph node—penile cancer	0.00298	0.0033	CbGeAlD
Bosutinib—FGR—lymph node—penile cancer	0.00296	0.00328	CbGeAlD
Bosutinib—LCK—lymph node—penile cancer	0.00296	0.00328	CbGeAlD
Bosutinib—AXL—lymph node—penile cancer	0.00295	0.00326	CbGeAlD
Bosutinib—EPHB2—Axon guidance—SCN10A—penile cancer	0.00291	0.0301	CbGpPWpGaD
Bosutinib—MAP2K1—L1CAM interactions—SCN10A—penile cancer	0.00289	0.03	CbGpPWpGaD
Bosutinib—SLK—lymph node—penile cancer	0.00284	0.00314	CbGeAlD
Bosutinib—EPHB4—lymph node—penile cancer	0.00282	0.00312	CbGeAlD
Bosutinib—PRKCQ—Axon guidance—SCN10A—penile cancer	0.00277	0.0287	CbGpPWpGaD
Bosutinib—EPHA2—lymph node—penile cancer	0.00276	0.00306	CbGeAlD
Bosutinib—FYN—lymph node—penile cancer	0.00276	0.00305	CbGeAlD
Bosutinib—MAP3K3—lymph node—penile cancer	0.0027	0.00298	CbGeAlD
Bosutinib—MAP4K5—lymph node—penile cancer	0.0027	0.00298	CbGeAlD
Bosutinib—EPHB3—Developmental Biology—SCN10A—penile cancer	0.00252	0.0261	CbGpPWpGaD
Bosutinib—EGFR—L1CAM interactions—SCN10A—penile cancer	0.00251	0.026	CbGpPWpGaD
Bosutinib—YES1—lymph node—penile cancer	0.00249	0.00276	CbGeAlD
Bosutinib—STK10—lymph node—penile cancer	0.00247	0.00273	CbGeAlD
Bosutinib—TAOK3—lymph node—penile cancer	0.00246	0.00272	CbGeAlD
Bosutinib—EPHA2—Axon guidance—SCN10A—penile cancer	0.00245	0.0253	CbGpPWpGaD
Bosutinib—SRC—lymph node—penile cancer	0.0024	0.00265	CbGeAlD
Bosutinib—FES—Developmental Biology—SCN10A—penile cancer	0.00237	0.0245	CbGpPWpGaD
Bosutinib—EPHA3—Developmental Biology—SCN10A—penile cancer	0.00225	0.0233	CbGpPWpGaD
Bosutinib—EPHA5—Developmental Biology—SCN10A—penile cancer	0.00225	0.0233	CbGpPWpGaD
Bosutinib—ABL2—Developmental Biology—SCN10A—penile cancer	0.00225	0.0233	CbGpPWpGaD
Bosutinib—MAP2K5—lymph node—penile cancer	0.0022	0.00244	CbGeAlD
Bosutinib—EPHA8—Developmental Biology—SCN10A—penile cancer	0.00217	0.0224	CbGpPWpGaD
Bosutinib—CSF1R—lymph node—penile cancer	0.00215	0.00238	CbGeAlD
Bosutinib—SRC—L1CAM interactions—SCN10A—penile cancer	0.00214	0.0222	CbGpPWpGaD
Bosutinib—EPHB4—Developmental Biology—SCN10A—penile cancer	0.00214	0.0222	CbGpPWpGaD
Bosutinib—EPHA4—Developmental Biology—SCN10A—penile cancer	0.00214	0.0222	CbGpPWpGaD
Bosutinib—EPHB2—Developmental Biology—SCN10A—penile cancer	0.00207	0.0215	CbGpPWpGaD
Bosutinib—PRKCQ—Developmental Biology—SCN10A—penile cancer	0.00198	0.0205	CbGpPWpGaD
Bosutinib—PDGFRB—lymph node—penile cancer	0.00191	0.00211	CbGeAlD
Bosutinib—ROCK1—Axon guidance—SCN10A—penile cancer	0.00184	0.019	CbGpPWpGaD
Bosutinib—EPHA2—Developmental Biology—SCN10A—penile cancer	0.00175	0.0181	CbGpPWpGaD
Bosutinib—ABL1—lymph node—penile cancer	0.0017	0.00188	CbGeAlD
Bosutinib—PTK2—Axon guidance—SCN10A—penile cancer	0.00152	0.0157	CbGpPWpGaD
Bosutinib—YES1—Axon guidance—SCN10A—penile cancer	0.0015	0.0155	CbGpPWpGaD
Bosutinib—ROCK1—Developmental Biology—SCN10A—penile cancer	0.00131	0.0136	CbGpPWpGaD
Bosutinib—MAP2K2—Axon guidance—SCN10A—penile cancer	0.00117	0.0121	CbGpPWpGaD
Bosutinib—LYN—Axon guidance—SCN10A—penile cancer	0.00112	0.0116	CbGpPWpGaD
Bosutinib—ABL1—Axon guidance—SCN10A—penile cancer	0.00111	0.0115	CbGpPWpGaD
Bosutinib—ABCB1—urethra—penile cancer	0.00111	0.00123	CbGeAlD
Bosutinib—FYN—Axon guidance—SCN10A—penile cancer	0.0011	0.0114	CbGpPWpGaD
Bosutinib—MAP2K1—Axon guidance—SCN10A—penile cancer	0.00109	0.0113	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—SCN10A—penile cancer	0.00108	0.0112	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—SCN10A—penile cancer	0.00107	0.0111	CbGpPWpGaD
Bosutinib—EGFR—Axon guidance—SCN10A—penile cancer	0.000949	0.00983	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—SCN10A—penile cancer	0.000834	0.00863	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—SCN10A—penile cancer	0.00081	0.00839	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—SCN10A—penile cancer	0.000796	0.00825	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—SCN10A—penile cancer	0.000793	0.00821	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—SCN10A—penile cancer	0.000784	0.00812	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—SCN10A—penile cancer	0.00078	0.00808	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—SCN10A—penile cancer	0.000677	0.00702	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—SCN10A—penile cancer	0.000578	0.00599	CbGpPWpGaD
Bosutinib—ABCB1—lymph node—penile cancer	0.000529	0.000585	CbGeAlD
